Cancer diagnostics company Neoprobe (NYSE Amex:NEOP) has sold its radiation-detection device business to Devicor Medical Products in a deal that could reach a value as high as $50 million. Devicor, a Wisconsin-based holding company backed by Chicago private equity firm GTCR Golder Rauner, has agreed to buy Neoprobe’s device business for $30 million in cash […]
Cancer diagnostics company Neoprobe (NYSE Amex:NEOP) shot back at critics of the company’s latest phase 3 clinical trial of its radiopharmaceutical Lymphoseek. “It’s clear this was the right study done the right way,” CEO Mark Pykett said during a conference call with investors and analysts to discuss the company’s first-quarter financial results. Pykett spent the […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
A phase 3 clinical trial showed Neoprobe‘s (NYSE Amex:NEOP) radiopharmaceutical Lymphoseek to be superior to the current standard of care in identifying cancerous lymph nodes in patients with breast cancer or melanoma. With the positive results of the trial in hand, Neoprobe CEO Mark Pykett reiterated the Dublin, Ohio’s company’s plans to file for regulatory […]
Cancer diagnostics firm Neoprobe (NYSE Amex:NEOP) has filed a regulatory document that gives it the right to sell up to $100 million in shares. However, the Dublin, Ohio-based company has no immediate plans to issue those new shares, CFO Brent Larson said. “This is just good corporate governance,” Larson said. “There are no plans to […]
Cancer diagnostics company Neoprobe (NYSE Amex:NEOP) has avoided a proxy fight with its largest shareholder by coming to an agreement with Platinum Montaur Life Sciences on board nominations. Platinum last month had threatened Neoprobe with a proxy fight aimed at installing three new directors on the Dublin, Ohio-based company’s board. Now, with Neoprobe agreeing to […]
The newly installed CEO of cancer diagnostics firm Neoprobe (NYSE Amex:NEOP) said the company is again delaying its FDA application to commercialize its radiopharmaceutical Lymphoseek. As recently as earlier this month, the company said it expected in the second quarter to file with the U.S. Food and Drug Administration a New Drug Application (NDA) for […]
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Among the life science current events from last week: who would buy Neoprobe, St. Jude's China strategy, a new Ohio biomedical seed fund, Cleveland Clinic's return on investment, seeking help from cyberspace to fight the medical device tax.
As cancer diagnostics firm Neoprobe (NYSE Amex: NEOP) marches toward FDA approval of its “game-changing” radiopharmaceutical Lymphoseek and its share price continues to climb, many of the company’s shareholders are likely wondering when they’ll get the chance to cash out. There’s certainly plenty of investor interest in the company. Neoprobe’s shares are up a whopping […]
Neoprobe‘s (NYSE Amex:NEOP) largest shareholder said it’s considering launching a proxy fight aimed at installing three new directors on the cancer diagnostics company’s board. Platinum-Montaur Life Sciences said in a regulatory filing that it is nominating three candidates for Dublin, Ohio-based Neoprobe’s board and that it “reserve[s] the right to solicit proxies to see that […]
Cancer diagnostics firm Neoprobe (NYSE Amex:NEOP) plans to file for U.S. regulatory approval of its cancer-tracing agent Lymphoseek next quarter. CEO David Bupp confirmed on a conference call with investors that the Dublin, Ohio company during the second quarter would file a New Drug Application (NDA) for the tracing agent with the U.S. Food and […]
Gabby Everett, the site director for BioLabs Pegasus Park, offered a tour of the space and shared some examples of why early-stage life science companies should choose North Texas.
Shares of Neoprobe (NYSE Amex:NEOP) continue their strong performance of recent weeks, rising by as much as 8 percent in early Friday trading after the company published results from a phase 2 clinical trial of its cancer-targeting agent.
Neoprobe (NYSE Amex:NEOP) has reached an agreement to license imaging technology from Naviscan. The combined technology could produce images that allow surgeons to more precisely target cancerous lymph nodes for removal.
It was a strange day on Wall Street for Neoprobe (AMEX: NEOP) as the company's shares hit a 52-week high while also ending the day down about 3 percent. The early surge may have been related to the company's continued progress on its drug Lymphoseek, a tracing agent that identifies cancerous lymph nodes in patients with breast cancer and melanoma.
Neoprobe Corp. (OTCBB:NEOP) has received approval for its common stock to be listed on the NYSE Amex.
Neoprobe Corp. (OTCBB:NEOP) continues to take steps down the regulatory path aimed at restarting development efforts for its RIGScan cancer-detecting technology.